HK1087336A1 - Pharmaceutical composition comprising lumiracoxib - Google Patents

Pharmaceutical composition comprising lumiracoxib

Info

Publication number
HK1087336A1
HK1087336A1 HK06107694.8A HK06107694A HK1087336A1 HK 1087336 A1 HK1087336 A1 HK 1087336A1 HK 06107694 A HK06107694 A HK 06107694A HK 1087336 A1 HK1087336 A1 HK 1087336A1
Authority
HK
Hong Kong
Prior art keywords
tablets
lumiracoxib
administration
pharmaceutical composition
fluoroanilino
Prior art date
Application number
HK06107694.8A
Other languages
English (en)
Inventor
Anees Abdulquadar Karnachi
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1087336A1 publication Critical patent/HK1087336A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06107694.8A 2001-08-31 2006-07-10 Pharmaceutical composition comprising lumiracoxib HK1087336A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31638901P 2001-08-31 2001-08-31
PCT/EP2002/009701 WO2003020261A1 (en) 2001-08-31 2002-08-30 Pharmaceutical composition comprising lumiracoxib

Publications (1)

Publication Number Publication Date
HK1087336A1 true HK1087336A1 (en) 2006-10-13

Family

ID=23228840

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107694.8A HK1087336A1 (en) 2001-08-31 2006-07-10 Pharmaceutical composition comprising lumiracoxib

Country Status (30)

Country Link
US (2) US20030114527A1 (es)
EP (1) EP1425005B1 (es)
JP (1) JP4636796B2 (es)
KR (1) KR100895551B1 (es)
CN (1) CN100406008C (es)
AR (1) AR036312A1 (es)
AT (1) ATE324883T1 (es)
AU (1) AU2002331094B2 (es)
BR (1) BR0212155A (es)
CA (1) CA2456604C (es)
CO (1) CO5560554A2 (es)
CY (1) CY1106137T1 (es)
DE (1) DE60211183T2 (es)
DK (1) DK1425005T3 (es)
EC (1) ECSP044986A (es)
ES (1) ES2263813T3 (es)
HK (1) HK1087336A1 (es)
HU (1) HUP0401429A2 (es)
IL (1) IL160375A0 (es)
MX (1) MXPA04001933A (es)
MY (1) MY137516A (es)
NO (1) NO20040860L (es)
NZ (1) NZ531342A (es)
PE (1) PE20030323A1 (es)
PL (1) PL367464A1 (es)
PT (1) PT1425005E (es)
RU (1) RU2329801C2 (es)
SI (1) SI1425005T1 (es)
WO (1) WO2003020261A1 (es)
ZA (1) ZA200400877B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
PE20040288A1 (es) * 2002-03-07 2004-06-24 Novartis Ag Composiciones farmaceuticas de acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EA018867B1 (ru) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
MX368159B (es) * 2014-01-10 2019-09-20 Johnson & Johnson Consumer Inc Proceso para elaborar tabletas con el uso de radiofrecuencia y partículas disipativas revestidas.
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701449B1 (en) * 1993-06-08 2003-08-06 Novartis AG Process for the preparation of an oral solid dosage form containing diclofenac
KR100373622B1 (ko) * 1996-05-17 2003-07-12 머크 앤드 캄파니 인코포레이티드 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas

Also Published As

Publication number Publication date
PL367464A1 (en) 2005-02-21
AU2002331094B2 (en) 2006-08-31
ZA200400877B (en) 2004-11-01
DE60211183D1 (de) 2006-06-08
ES2263813T3 (es) 2006-12-16
US20070231382A1 (en) 2007-10-04
MXPA04001933A (es) 2004-06-15
HUP0401429A2 (hu) 2004-11-29
BR0212155A (pt) 2004-07-13
EP1425005A1 (en) 2004-06-09
NO20040860L (no) 2004-04-22
WO2003020261A1 (en) 2003-03-13
SI1425005T1 (sl) 2006-12-31
RU2329801C2 (ru) 2008-07-27
DE60211183T2 (de) 2007-02-01
RU2004109920A (ru) 2005-04-20
KR20040031019A (ko) 2004-04-09
CN100406008C (zh) 2008-07-30
PT1425005E (pt) 2006-09-29
EP1425005B1 (en) 2006-05-03
MY137516A (en) 2009-02-27
JP2005520785A (ja) 2005-07-14
IL160375A0 (en) 2004-07-25
JP4636796B2 (ja) 2011-02-23
KR100895551B1 (ko) 2009-04-29
PE20030323A1 (es) 2003-05-12
AR036312A1 (es) 2004-08-25
CO5560554A2 (es) 2005-09-30
CA2456604C (en) 2011-02-08
NZ531342A (en) 2005-09-30
ECSP044986A (es) 2004-04-28
ATE324883T1 (de) 2006-06-15
DK1425005T3 (da) 2006-09-04
US20030114527A1 (en) 2003-06-19
CY1106137T1 (el) 2011-06-08
CN1728993A (zh) 2006-02-01
CA2456604A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
WO2004112711A3 (en) Oral extended-release composition
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
BG108516A (en) Pharmaceutical formulation
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
ES2130081B1 (es) Comprimido de maleato de trimebutina con recubrimiento laminar.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
WO2003099214A3 (en) Biguanide formulations
GEP20043377B (en) Pharmaceutical Complex
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa
HUP0200148A2 (hu) N-(3',4'-dimetoxi-cinnamoil)antranilsav alkalmazása szívkoszorúér-műtéttel kapcsolatos cardiovascularis események megelőzésére vagy mérséklésére

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120830